For instance, HDACi and BTKi could increase the efficacy of rituximab by upregulating CD20 surface expression and enhancing NK cell-mediated antibody-dependent cell-mediated cytotoxicity effect.70,73 The combination of Bcl-2 inhibitor with rituximab or CHOP can synergistically enhance their anti-tumor effect.35,74 Furthermore, HDACi could act synergistically with Bcl-2 inhibitor and BTKi to improve anti-tumor effects.36,75 Effectively improving the synergistic effects of these medications can result in a treatment plan that is greater than the sum of its parts. The gene discussed is DDIT3; the disease is neoplasm.